EP Meeting: Orphan Drugs for Rare Cancers
Parliamentary Meeting on Orphan Drugs for Rare Cancers: Proposals for Action at the European Level
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Parliamentary Meeting on Orphan Drugs for Rare Cancers: Proposals for Action at the European Level
High-grade glioma and leptomeningeal metastasis guidelines are currently provided
Providing guidelines on more than 15 topics in lymphoma, leukaemia and myeloma
Comprehensive guidance on cervical, endometrial and ovarian cancers. Also including gestational trophoblastic disease guidelines
Nasopharyngeal cancer and HNSCC guidelines are included covering diagnosis through to follow-up.
Comprehensive guidelines on early, locally advanced and metastatic NSCLC, SCLC, malignant pleural mesothelioma and thymic epithelial tumours
Supportive and palliative care are areas of high importance in oncology and ESMO published Clinical Practice Guidelines on the management of a variety of issues
Topics include prostate, urothelial bladder, testicular, penile and renal cell cancers
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.